Evercore ISI Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price boosted by analysts at Evercore ISI from $220.00 to $260.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Evercore ISI's target price would suggest a potential upside of 70.57% from the stock's previous close.

ASND has been the topic of a number of other research reports. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of "Moderate Buy" and a consensus price target of $200.21.

Ascendis Pharma A/S Trading Down 1.4 %

Shares of NASDAQ:ASND traded down $2.15 during trading on Tuesday, hitting $152.43. 444,151 shares of the company's stock traded hands, compared to its average volume of 509,524. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The company has a market cap of $9.25 billion, a price-to-earnings ratio of -21.47 and a beta of 0.64. The company has a 50-day moving average price of $134.54 and a 200-day moving average price of $133.07.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at $28,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $30,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the period. Blue Trust Inc. lifted its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.